Real-time Price Updates for Astrazeneca Plc ADR (AZN-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Market Implications: The successful development of tozorakimab could positively impact AstraZeneca’s stock, as it addresses a significant need in COPD treatment.

Roche is the outlier to this, however, with astegolimab currently more advanced in COPD trials than in asthma. AstraZeneca’s drug, tozorakimab, also blocks IL-33 and failed to meet the primary ...

Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the condition. Read more here.

Roche’s hopes of getting astegolimab to regulators this year took a hit after the anti-ST2 antibody failed to reduce flare-ups in a phase 3 study.

Tozorakimab, an anti-IL-33 antibody, improves lung function and may reduce exacerbations in high-risk COPD patients, early trial data suggest.

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly lower disease exacerbation rates versus placebo in patients with chronic ...

AstraZeneca has launched a Phase IIb clinical study titled ‘A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in ...